Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis
Published: November 22 2021
Abstract Views: 7223
PDF: 945
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Since the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic outbreak, vaccines gained a growing role. Possible vaccine-related side effects range from minor local events to more prominent systemic manifestations up to anaphylactic reactions. A heterogeneous spectrum of cutaneous reactions has been reported, ranging from local injection site reactions to urticarial and morbilliform eruptions, pernio/chilblains and zoster flares. Here, we describe a case of varicella zoster virus reactivation following mRNA coronavirus 2019 vaccine and discuss the available literature upon the topic published so far.
Altmetrics
Downloads
Download data is not yet available.
Citations
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27). [Epub ahead of print].
Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013; 369: 255-63. DOI: https://doi.org/10.1056/NEJMcp1302674
Walter R, Hartmann K, Fleisch F, et al. Reactivation of herpesvirus infections after vaccinations? Lancet (London, England). 1999; 353: 810. DOI: https://doi.org/10.1016/S0140-6736(99)00623-6
Bostan E, Yalici-Armagan B. Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence? J Cosmet Dermatol. 2021; 20: 1566-7. DOI: https://doi.org/10.1111/jocd.14035
Eid E, Abdullah L, Kurban M, Abbas O. Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol. 2021; 93: 5231-2. DOI: https://doi.org/10.1002/jmv.27036
McMahon DE, Amerson A, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021; 85: 46-55. DOI: https://doi.org/10.1016/j.jaad.2021.03.092
Furer V, Zisman D, Kibari A, et al. Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology (Oxford, England). 2021. [Epub ahead of print]. DOI: https://doi.org/10.1093/rheumatology/keab702
Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019; 10: 594. DOI: https://doi.org/10.3389/fimmu.2019.00594
Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; 5: e001041. DOI: https://doi.org/10.1136/rmdopen-2019-001041
How to Cite
Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis. (2021). Reumatismo, 73(3). https://doi.org/10.4081/reumatismo.2021.1445
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Linda Mastromanno, Federico Giardina, Angelica Gattamelata, Serena Colafrancesco, Simona Truglia, Francesca Romana Spinelli, Edoardo Simoncelli, Bruno Lucchino, Fabrizio Conti, Roberta Priori, Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease , Reumatismo: Early Access
- J. N. Ablin, V. Aloush, A. Brill, M. Berman, M. Barzilai, D. Caspi, M. Mandelboim, D. Levartovsky, A. Polachek, Y. Wolman, D. Paran, M. Barkagan, O. Elkayam, Influenza vaccination is safe and effective in patients suffering from fibromyalgia syndrome , Reumatismo: Vol. 67 No. 2 (2015)
- B. Maranini, G. Ciancio, M. Corazza, F. Ruffilli, G. Galoppini, M. Govoni, Erythema nodosum after COVID-19 vaccine , Reumatismo: Vol. 74 No. 1 (2022)
- S. Batıbay, R. Koçak Ulucaköy, Z. Günendi, F. Göğüş, The prevalence and clinical spectrum of post-Covid syndrome in patients with rheumatic diseases: a single-center experience , Reumatismo: Vol. 74 No. 1 (2022)
- D. Mohamadzadeh, S. Assar, M. Pournazari, P. Soufivand, S. Danaei, Disseminated cutaneous herpes simplex infection after COVID-19 vaccination in a rheumatoid arthritis patient: a case report and review , Reumatismo: Vol. 74 No. 2 (2022)
- A. Camargo-Coronel, H. Quiñones-Moya, M.R. Hernández-Zavala, J.R. Hernández-Vázquez, M.Á. Vázquez-Zaragoza, Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review , Reumatismo: Vol. 75 No. 1 (2023)
- N. Ughi, D.P. Bernasconi, C. Gagliardi, F. Del Gaudio, A. Dicuonzo, A. Maloberti, C. Giannattasio, C. Rossetti, M.G. Valsecchi, O.M. Epis, Trends in severe outcomes in SARS-CoV-2-positive hospitalized patients with rheumatic diseases: a monocentric observational and case-control study in northern Italy , Reumatismo: Vol. 75 No. 2 (2023)
- B. Maranini, G. Ciancio, R. Cultrera, M. Govoni, Reply to: “Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab” by Josef Finsterer , Reumatismo: Vol. 74 No. 1 (2022)
- J. Finsterer, Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab , Reumatismo: Vol. 74 No. 1 (2022)
- Y. Emad, T. Gheita, H. Darweesh, P. Klooster, R. Gamal, H. Fathi, N. El-Shaarawy, M. Gamil, M. Hawass, R.M. El-Refai, H. Al-Hanafi, S. Abd-Ellatif, A. Ismail, J. Rasker, Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity , Reumatismo: Vol. 70 No. 2 (2018)
1-10 of 433
Next
You may also start an advanced similarity search for this article.
